Research Square (Research Square),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Nov. 11, 2022
Abstract
The
purpose
of
this
retrospective,
longitudinal
study
is
to
evaluate
the
relationship
between
MD
slope
from
visual
field
tests
collected
over
a
short
period
time
(2
years)
and
current
United
States’
Food
Drug
Administration
(FDA)
recommended
endpoints
for
outcomes.
If
correlation
strong
highly
predictive,
clinical
trials
employing
slopes
as
primary
could
be
employed
in
neuroprotection
with
shorter
duration
help
expedite
development
novel
IOP-independent
therapies.
Visual
patients
or
suspected
glaucoma
were
selected
an
academic
institution
evaluated
based
on
two
functional
progression
endpoints:
1)
five
more
locations
worsening
by
at
least
7
dB,
2)
5
test
upon
GCP
algorithm.
A
total
467
(76.6%)
472
(77.4%)
eyes
reached
Endpoints
B,
respectively,
any
point
time.
359
(58.8%)
progressed
faster
than
0
dB/year,
278
(45.5%)
-0.5
200
(32.7%)
-1.0
dB/year.
It
was
found
that
experiencing
rapid
24-2
2-year
likely
reach
one
FDA
accepted
during
soon
after
period.
ACS Omega,
Journal Year:
2024,
Volume and Issue:
9(24), P. 25756 - 25765
Published: June 6, 2024
Degeneration
of
the
retina
is
intrinsically
associated
with
pathogenesis
and
progression
neurodegenerative
diseases.
However,
cellular
molecular
mechanisms
underlying
association
between
neurodegeneration
retinal
degeneration
are
still
under
exploration
due
to
complexity
connectivity
network
nervous
system.
In
this
study,
RNA-seq
data
from
brains
model
retinitis
pigmentosa
(RP)
mice
previously
studied
Parkinson's
disease
(PD)
were
analyzed
explore
commonalities
degenerative
Differentially
expressed
genes
in
RP
compared
disease-related
intersecting
identified,
including
Cnr1
Septin14.
These
verified
by
quantitative
real-time
reverse
transcription
PCR
Western
blotting
experiments.
The
key
proteins
CNR1
SEPTIN14
found
be
potential
cotherapeutic
targets
for
disease.
conclusion,
understanding
diseases
processes
brain
will
not
only
facilitate
interpretation
pathomechanisms
but
also
contribute
early
diagnosis
development
new
therapeutic
strategies.
Journal of Neuro-Ophthalmology,
Journal Year:
2023,
Volume and Issue:
unknown
Published: July 12, 2023
Abstract
Optic
neuropathies
encompass
a
breadth
of
diseases
that
ultimately
result
in
dysfunction
and/or
loss
retinal
ganglion
cells
(RGCs).
Although
visual
impairment
from
optic
is
common,
there
lack
effective
clinical
treatments.
Addressing
critical
need
for
novel
interventions,
preclinical
studies
have
been
generating
growing
body
evidence
identify
promising
new
drug-based
and
cell-based
therapies.
Gene
therapy
another
emerging
therapeutic
field
offers
the
potential
specifically
robustly
increasing
long-term
RGC
survival
neuropathies.
additional
benefits
driving
improvements
following
single
treatment
administration,
it
can
be
designed
to
target
variety
pathways
may
involved
individual
or
across
multiple
etiologies.
This
review
explores
history
gene
therapy,
fundamentals
its
application,
development
technology
as
relates
Research Square (Research Square),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Nov. 11, 2022
Abstract
The
purpose
of
this
retrospective,
longitudinal
study
is
to
evaluate
the
relationship
between
MD
slope
from
visual
field
tests
collected
over
a
short
period
time
(2
years)
and
current
United
States’
Food
Drug
Administration
(FDA)
recommended
endpoints
for
outcomes.
If
correlation
strong
highly
predictive,
clinical
trials
employing
slopes
as
primary
could
be
employed
in
neuroprotection
with
shorter
duration
help
expedite
development
novel
IOP-independent
therapies.
Visual
patients
or
suspected
glaucoma
were
selected
an
academic
institution
evaluated
based
on
two
functional
progression
endpoints:
1)
five
more
locations
worsening
by
at
least
7
dB,
2)
5
test
upon
GCP
algorithm.
A
total
467
(76.6%)
472
(77.4%)
eyes
reached
Endpoints
B,
respectively,
any
point
time.
359
(58.8%)
progressed
faster
than
0
dB/year,
278
(45.5%)
-0.5
200
(32.7%)
-1.0
dB/year.
It
was
found
that
experiencing
rapid
24-2
2-year
likely
reach
one
FDA
accepted
during
soon
after
period.
